Sunday, 23 July 2017

Sanofi to buy vaccines biotech company

12 July 2017 | News

Under the terms of the agreement, Sanofi will make an upfront payment of $650 million for Protein Sciences, and pay up to $100 million upon the achievement of certain milestones.

French drugmaker and healthcare group Sanofi is to buy privately-held U.S vaccines biotech company Protein Sciences for an initial amount of $650 million, as Sanofi steps up its acquisition program after recently missing two large deals.

Under the terms of the agreement, Sanofi will make an upfront payment of $650 million for Protein Sciences, and pay up to $100 million upon the achievement of certain milestones.

Sanofi missed out to Johnson & Johnson on buying Switzerland's biotech Actelion in January - a $30 billion deal - and was also beaten in August last year by a $14 billion bid for cancer specialist Medivation from Pfizer.

The acquisition of Protein Sciences will allow Sanofi to broaden their flu portfolio with the addition of a non-egg based vaccine.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Survey Box

Is value- based patient healthcare system more effective in Asian countries?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls